SVP and President, Healthcare Majors Cary L sold $365,532 worth of Ordinary Shares (1,682 units at $217.32), decreasing direct ownership by 13% to 11,372 units (SEC Form 4)

$STE
Industrial Specialties
Health Care
Get the next $STE alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Majors Cary L

(Last) (First) (Middle)
C/O 70 SIR JOHN ROGERSON'S QUAY

(Street)
DUBLIN 2 L2 D02 R296

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP and President, Healthcare
3. Date of Earliest Transaction (Month/Day/Year)
11/25/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 11/25/2024 S 1,682 D $217.32(1) 11,372(2) D
Ordinary Shares 67 I See Footnote Below(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Price reflects a weighted average sale price for multiple transactions ranging from $217.32 to $217.40 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of ordinary shares sold at each separate price.
2. As of November 27, 2024, 9,872 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 1,964 on June 2, 2025; 692 on October 1, 2025; 2,697 on June 1, 2026; 2,140 on June 2, 2026 and 2,379 on June 4, 2027.
3. Units representing 67 ordinary share equivalents are held on behalf of the Reporting Person under the STERIS Corporation 401(k) Plan as of November 25, 2024.
/s/ John P. Ubbing, Authorized Representative under Power of Attorney 11/27/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $STE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$STE

DatePrice TargetRatingAnalyst
10/24/2024$230.00 → $260.00Neutral → Overweight
Piper Sandler
2/6/2024$253.00Overweight
KeyBanc Capital Markets
5/30/2023$206.00Equal-Weight
Morgan Stanley
4/14/2023$215.00 → $197.00Overweight → Neutral
Piper Sandler
9/23/2022Buy → Hold
Needham
7/14/2022$240.00Overweight
Piper Sandler
4/7/2022$275.00Outperform
Wolfe Research
2/14/2022$250.00 → $270.00Market Outperform
JMP Securities
More analyst ratings

$STE
Press Releases

Fastest customizable press release news feed in the world

See more
  • STERIS Announces Financial Results for Fiscal 2025 Third Quarter

    Total revenue from continuing operations increased 6%; constant currency organic revenue grew 6% As reported diluted EPS from continuing operations increased to $1.75; adjusted EPS increased to $2.32Fiscal 2025 outlook updated DUBLIN, IRELAND, Feb. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 third quarter ended December 31, 2024. Total revenue from continuing operations for the third quarter of fiscal 2025 increased 6% to $1.4 billion compared with $1.3 billion in the third quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the third quarter also increased 6%. "

    $STE
    Industrial Specialties
    Health Care
  • STERIS Declares Dividend of $0.57 per share

    DUBLIN, IRELAND, Jan. 28, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on March 21, 2025, to shareholders of record at the close of business on February 20, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life sciences product

    $STE
    Industrial Specialties
    Health Care
  • STERIS to Host a Conference Call for Fiscal 2025 Third Quarter Financial Results on February 6, 2025

    DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 third quarter financial results at 9:00 a.m. ET on February 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 5, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 6, 2

    $STE
    Industrial Specialties
    Health Care

$STE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$STE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$STE
SEC Filings

See more

$STE
Leadership Updates

Live Leadership Updates

See more
  • STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

    DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

    $CDMO
    $STE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
  • STERIS Announces Changes to Board of Directors

    David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W

    $STE
    Industrial Specialties
    Health Care

$STE
Financials

Live finance-specific insights

See more
  • STERIS Announces Financial Results for Fiscal 2025 Third Quarter

    Total revenue from continuing operations increased 6%; constant currency organic revenue grew 6% As reported diluted EPS from continuing operations increased to $1.75; adjusted EPS increased to $2.32Fiscal 2025 outlook updated DUBLIN, IRELAND, Feb. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 third quarter ended December 31, 2024. Total revenue from continuing operations for the third quarter of fiscal 2025 increased 6% to $1.4 billion compared with $1.3 billion in the third quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the third quarter also increased 6%. "

    $STE
    Industrial Specialties
    Health Care
  • STERIS Declares Dividend of $0.57 per share

    DUBLIN, IRELAND, Jan. 28, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on March 21, 2025, to shareholders of record at the close of business on February 20, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life sciences product

    $STE
    Industrial Specialties
    Health Care
  • STERIS to Host a Conference Call for Fiscal 2025 Third Quarter Financial Results on February 6, 2025

    DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 third quarter financial results at 9:00 a.m. ET on February 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 5, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 6, 2

    $STE
    Industrial Specialties
    Health Care

$STE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more